Literature DB >> 28577076

68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?

Christian Uprimny1.   

Abstract

Ever since the introduction of 68Ga-prostate-specific membrane antigen 11 positron-emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) a few years ago, it has rapidly achieved great success in the field of prostate cancer imaging. A large number of studies have been published to date, indicating a high potential of 68Ga-PSMA-11 PET/CT in the work-up of prostate cancer patients, including primary diagnosis, staging and biochemical recurrence. The aim of this review is to present the most important data on this novel, highly promising imaging technique, and to formulate recommendations for possible applications of 68Ga-PSMA-11 PET/CT in clinical routine.

Entities:  

Keywords:  68Ga-PSMA-11 PET/CT; Biochemical recurrence; Indication; Prostate cancer; Staging

Mesh：

Substances：

Year:  2017        PMID： 28577076     DOI： 10.1007/s10354-017-0569-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  65 in total

1.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Authors:  L Bubendorf; A Schöpfer; U Wagner; G Sauter; H Moch; N Willi; T C Gasser; M J Mihatsch
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

2.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors:  Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

3.  Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Authors:  Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes
Journal:  Pathol Oncol Res       Date:  2008-09-18       Impact factor: 3.201

4.  Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker.

Authors: 
Journal:  Mol Urol       Date:  1999

5.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Authors:  S S Chang; D S O'Keefe; D J Bacich; V E Reuter; W D Heston; P B Gaudin
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

6.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.

Authors:  Sangeeta Ray Banerjee; Mrudula Pullambhatla; Youngjoo Byun; Sridhar Nimmagadda; Gilbert Green; James J Fox; Andrew Horti; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

7.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors:  Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

Review 8.  A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.

Authors:  M J Beresford; D Gillatt; R J Benson; T Ajithkumar
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-11-30       Impact factor: 4.126

Review 9.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Authors:  Arundhati Ghosh; Warren D W Heston
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429

Review 10.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.

Authors:  A M Hövels; R A M Heesakkers; E M Adang; G J Jager; S Strum; Y L Hoogeveen; J L Severens; J O Barentsz
Journal:  Clin Radiol       Date:  2008-02-04       Impact factor: 2.350
View more
  4 in total

Review 1.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

2.  Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.

Authors:  Christian Uprimny; Steffen Bayerschmidt; Alexander Stephan Kroiss; Josef Fritz; Bernhard Nilica; Anna Svirydenka; Clemens Decristoforo; Gianpaolo di Santo; Elisabeth von Guggenberg; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-08       Impact factor: 9.236

Review 3.  Advances in prostate-specific membrane antigen PET of prostate cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2018-05       Impact factor: 3.645

Review 4.  New Radionuclides and Technological Advances in SPECT and PET Scanners.

Authors:  Nicholas P van der Meulen; Klaus Strobel; Thiago Viana Miranda Lima
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.